Author: Jackwood, M.W.; Rosenbloom, R.; Petteruti, M.; Hilt, D.A.; McCall, A.W.; Williams, S.M.
Title: Avian coronavirus infectious bronchitis virus susceptibility to botanical oleoresins and essential oils in vitro and in vivo Cord-id: qgpi2kcs Document date: 2010_1_21
ID: qgpi2kcs
Snippet: Anti-coronaviral activity of a mixture of oleoresins and essential oils from botanicals, designated QR448(a), was examined in vitro and in vivo. Treatment of avian infectious bronchitis virus (IBV) with QR448(a) reduced the virus titer as measured in two laboratory host systems, Vero E6 cells and embryonating eggs. The effect of QR448(a) on IBV in chickens was also investigated. Administering QR448(a) to chickens at a 1:20 dilution by spray, 2 h before challenge with IBV was determined to be the
Document: Anti-coronaviral activity of a mixture of oleoresins and essential oils from botanicals, designated QR448(a), was examined in vitro and in vivo. Treatment of avian infectious bronchitis virus (IBV) with QR448(a) reduced the virus titer as measured in two laboratory host systems, Vero E6 cells and embryonating eggs. The effect of QR448(a) on IBV in chickens was also investigated. Administering QR448(a) to chickens at a 1:20 dilution by spray, 2 h before challenge with IBV was determined to be the most effective treatment. Treatment decreased the severity of clinical signs and lesions in the birds, and lowered the amount of viral RNA in the trachea. Treatment with QR448(a) protected chickens for up to 4 days post-treatment from clinical signs of disease (but not from infection) and decreased transmission of IBV over a 14-day period. Anti-IBV activity of QR448(a) was greater prior to virus attachment and entry indicating that the effect is virucidal. In addition, QR448(a) had activity against both Massachusetts and Arkansas type IB viruses, indicating that it can be expected to be effective against IBV regardless of serotype. To our knowledge, this is the first report on the in vivo use of a virucidal mixture of compounds effective against the coronavirus IBV.
Search related documents:
Co phrase search for related documents- acceptor inhibitor and acute respiratory syndrome virus: 1
- activity duration and acute respiratory syndrome: 1, 2
- activity duration and acute respiratory syndrome virus: 1
- activity duration and additional time: 1
- acute respiratory syndrome and additional time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute respiratory syndrome and adequate number: 1, 2, 3, 4
- acute respiratory syndrome and administration route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and administration timing: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute respiratory syndrome and administration timing optimal route: 1
- acute respiratory syndrome coronavirus and additional time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute respiratory syndrome coronavirus and adequate number: 1, 2
- acute respiratory syndrome coronavirus and administration route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- acute respiratory syndrome coronavirus and administration timing: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute respiratory syndrome coronavirus and administration timing optimal route: 1
- acute respiratory syndrome virus and additional time: 1, 2
- acute respiratory syndrome virus and adequate number: 1
- acute respiratory syndrome virus and administration route: 1, 2
- ad libitum and additional time: 1
- additional time and administration timing: 1
Co phrase search for related documents, hyperlinks ordered by date